Search

everythinglearnresearchcommunity

for

Search:↓

HPV genes and estradiol increase a cancer-related signaling pathway, which may be targeted for cervical cancer treatment.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.

LGD1069 effectively prevents breast tumors in mice without toxicity.

CDK4/6 inhibitors generally maintain quality of life in metastatic breast cancer patients, except for some side effects like diarrhea and hair loss.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.

Nilotinib can cause skin issues like red bumps and hair loss.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.

Baricitinib improved nail condition and hair regrowth in a patient with alopecia and nail abnormalities.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Ruxolitinib can help regrow hair in severe alopecia areata.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Trichohyalin in hair can trigger immune attacks in alopecia areata.

JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.

People with alopecia areata have higher levels of a heart disease marker in their blood.

Targeting THY1 can improve skin repair and healing.

Upadacitinib effectively treats severe alopecia areata and is safe.

Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.

Ticagrelor works better than clopidogrel in reducing platelet activity in elderly patients with acute coronary syndrome.

Retinoic acids temporarily change skin stem cells to a slower cycle and more differentiated state.